BioSyent Inc. (CVE:RX) Insider Sells C$2,566,496.00 in Stock

BioSyent Inc. (CVE:RX) insider FAX Capital Corp. sold 230,800 shares of the company’s stock in a transaction on Friday, November 22nd. The shares were sold at an average price of C$11.12, for a total transaction of C$2,566,496.00.

BioSyent Price Performance

RX stock opened at C$11.51 on Thursday. The company has a market capitalization of C$133.40 million, a PE ratio of 19.20 and a beta of 0.93. The company has a quick ratio of 6.91, a current ratio of 6.13 and a debt-to-equity ratio of 3.19. The stock’s 50 day moving average is C$11.08 and its two-hundred day moving average is C$10.32. BioSyent Inc. has a 52-week low of C$8.24 and a 52-week high of C$11.74.

BioSyent (CVE:RX) last posted its quarterly earnings results on Monday, August 26th. The company reported C$0.13 earnings per share (EPS) for the quarter, meeting the consensus estimate of C$0.13. BioSyent had a net margin of 21.14% and a return on equity of 20.88%. The firm had revenue of C$8.95 million for the quarter, compared to analysts’ expectations of C$8.80 million. Analysts predict that BioSyent Inc. will post 0.6944444 earnings per share for the current fiscal year.

BioSyent Company Profile

BioSyent Inc, together with its subsidiaries, acquires or licenses, develops, and sells pharmaceutical and other healthcare products in Canada and internationally. Its products include FeraMAX Pd Therapeutic 150 for the treatment of iron deficiency anemia; FeraMAX Pd Maintenance 45, a chewable supplement for the prevention of iron deficiency anemia; and FeraMAX Pd Powder 15, a powder form product used for preventing iron deficiency and iron deficiency anemia.